Integrity Applications (NASDAQ:IGAP – Get Rating) and NovoCure (NASDAQ:NVCR – Get Rating) are both medical companies, but which is the better deal? We’ll compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, and risk.
Score & Rating
This table compares revenue, earnings per share and valuation for Integrity Applications and NovoCure.
| gross receipts | price/sales ratio | net income | earnings per share | price-earnings ratio | |
| integrity applications | N / A | N / A | N / A | N / A | N / A |
| NovoCure | $535.03 million | 18.21 | -$58.35 million | ($0.77) | -120.56 |
Integrity Applications has higher revenue but lower revenue than NovoCure.
Analyst Recommendations
This is a summary of the latest reviews and price targets for Integrity Applications and NovoCure as provided by MarketBeat.
| sell reviews | keep ratings | Buy reviews | Strong buy recommendations | rating score | |
| integrity applications | N / A | ||||
| NovoCure | 1 | 3 | 4 | 2.38 |
NovoCure has a consensus target of $110.13, indicating a potential upside of 18.63%. Given NovoCure’s more likely upside, analysts clearly believe NovoCure is cheaper than Integrity Applications.
Insider and Institutional Property
78.4% of NovoCure shares are owned by institutional investors. 6.2% of NovoCure shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments, and large money managers believe a stock will outperform the market over the long term.
Risk & Volatility
Integrity Applications has a beta of -1.66, indicating its stock price is 266% less volatile than the S&P 500. In comparison, NovoCure has a beta of 0.78, indicating its stock price is 22% less is more volatile than the S&P 500.
profitability
This table compares the net margins, return on equity and return on total assets of Integrity Applications and NovoCure.
| net margins | return on equity | return on investment | |
| integrity applications | N / A | N / A | N / A |
| NovoCure | -15.05% | -18.85% | -7.06% |
summary
NovoCure beats Integrity Applications on 6 of the 9 factors comparing the two stocks.
About integrity applications
(received rating)
Integrity Applications, Inc. designs, develops and markets non-invasive glucose monitoring devices for use by individuals suffering from diabetes. The company offers the GlucoTrack model DF-F glucose monitor, which uses a patented combination of ultrasonic, electromagnetic, and thermal technologies to obtain glucose readings in under a minute via a small sensor that attaches to the earlobe and uses a small , portable control and display unit, all without drawing blood or interstitial fluid. It is designed to help people with diabetes and pre-diabetics get glucose levels without pain. The company was founded in September 2001 by Avner Gal and David Malka and is headquartered in Ashkelon, Israel.
About NovoCure
(received rating)
NovoCure Limited, an oncology company, is engaged in the development, manufacture and marketing of TTFields (Tumor Treating Fields) devices for the treatment of solid tumors in the United States, Europe, the Middle East, Africa, Japan and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The Company also has ongoing or completed clinical trials evaluating TTFields in brain metastasis, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Receive daily news and reviews for health applications – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Integrity Applications and related companies with MarketBeat.com’s FREE daily email newsletter.
